2nd International Hereditary Cancer Congress, 5-8 February 2026, Antalya
Cancer continues to be one of the most significant health challenges facing humanity today. Despite advancements in treatment strategies, the complex nature of the disease increasingly highlights the need for personalized and effective approaches. Hereditary cancers, in particular, represent a crucial area requiring specific risk and management strategies for both individuals and their families.
In this context, the 2nd International Hereditary Cancer Congress will be held from February 5-8, 2026, in Antalya, at the Rixos Premium Belek Hotel, to address groundbreaking developments in genetic predisposition, early diagnosis, risk management, and treatment approaches. Bringing together leading figures from the scientific community, this congress aims to share current knowledge in hereditary cancer, discuss multidisciplinary approaches, and define future strategies. It is of great importance in these aspects.
The congress program covers a broad spectrum, from diagnosis to treatment, genetic engineering to ethical considerations, offering participants a comprehensive platform for learning and interaction. This congress will be a significant step towards unraveling the mysteries of hereditary cancers for healthcare professionals, researchers, and anyone interested in this field.
📅 February 5, 2026 – Thursday: Opening and Looking Towards the Future
The first day of the congress will begin with opening remarks by Prof. Dr. Mustafa Özdoğan, followed by a series of impactful keynote talks exploring the personal and societal dimensions of hereditary cancer. The program will continue with cutting-edge scientific sessions and conclude with a welcoming cocktail reception.
- 🕒 14:00 – 14:30 | Opening Ceremony – Prof. Dr. Mustafa Özdoğan
Session Chair: Mustafa Özdoğan – Medical Genetics - 🕒 14:30 – 15:00 | “When Care Becomes Personal: A Nurse’s Journey Through a BRCA Legacy”
Speaker: Violet Aroyo - 🕒 15:00 – 15:30 | “Hereditary Cancer: A Collective Legacy, A Shared Responsibility”
Speaker: Fuat Demirelli - ☕ 15:30 – 16:00 | Coffee Break
Session Chairs: Oncology, Genetics - 🧠 16:00 – 16:45 | Keynote Lecture: “When DNA Isn’t Destiny: Reframing Genetic Risk in the Age of Polygenic Scores and Prevention”
Invited International Speaker - 🧬 16:45 – 17:15 | New Horizons of Genetic Engineering in Hereditary Cancers
- 🧪 17:15 – 17:45 | Population Genomic Screening for Inherited Cancer Risk: Clinical and Ethical Considerations
- 🍷 18:15 – 19:15 | Opening Cocktail Reception
📅 February 6, 2026 – Friday: Risk Management and Genomic Approaches in Hereditary Cancers
The second day of the congress focuses on risk management, advanced genomic technologies for unresolved cases, and precision medicine in hereditary cancers. Panels and symposia will promote interactive learning and cross-disciplinary collaboration.
- 🧭 Risk Management in Hereditary Cancers
Session Chairs: Oncology, Genetics - 🕘 09:00 – 09:30 | Identify and Risk Evaluation
- 🕘 09:30 – 10:00 | From Clinical Management to Early Detection
- ☕ 10:00 – 10:30 | Coffee Break
- 🔬 Genomic Approaches in Unsolved Cases – MultiOmic
Session Chairs: Oncology, Genetics - 🕥 10:30 – 11:00 | Long-Read Whole Genome Sequencing (WGS)
- 🕚 11:00 – 11:30 | RNA-Seq and Transcriptomic Insights
- 🕦 11:30 – 12:00 | Epigenome and Regulatory Layers
- 🍽 12:30 – 13:30 | Lunch Break
- 🛰 13:30 – 14:00 | Satellite Symposium
Moderator to be approved in coordination with sponsor - 👥 Panel: Herediboard – Case Discussions
14:00 – 15:00 | Session Chairs: Oncology, Genetics
Two cases: presented by oncology/genetics fellows or specialists
Panel: 2 oncologists + 2 geneticists - ☕ 15:00 – 15:30 | Coffee Break
- 🧬 Precision Medicine in Hereditary Cancers
Session Chairs: Oncology, Genetics - 🕞 15:30 – 16:00 | PARP Inhibitors in Germline-Driven Cancers: Current Clinical Practice and Future Directions
- 🕓 16:00 – 16:30 | Personalized Therapies and Clinical Trials in Germline Mutations Beyond BRCA
- 🕟 16:30 – 17:00 | Neoantigen Vaccine Strategies and Clinical Trials in Hereditary Cancer Immunotherapy
- 🕔 17:00 – 17:30 | Treatment Strategies for Hereditary Cancers Using CRISPR and Gene Editing Approaches
📅 February 7, 2026 – Saturday: Rare Syndromes, Genetic Counseling, and Hereditary Risks in Children
The third day of the congress delves into high-risk hereditary cancer syndromes with low clinical recognition, the evolving challenges in genetic counseling, novel reproductive technologies, and pediatric cancer predisposition syndromes.
- 🧬 High-Risk Syndromes, Low Recognition: Li-Fraumeni and Lynch in Clinical Practice
Session Chairs: Oncology, Genetics - 🕘 09:00 – 09:30 | Diagnosis and Management of Li-Fraumeni Syndrome
- 🕘 09:30 – 10:00 | The Evolution of Immunotherapy in Lynch Syndrome: New Treatment Paradigms for MSI-High Tumors
- ☕ 10:00 – 10:30 | Coffee Break
- 🧠 The Expanding Genome, the Rising Burden: Rethinking Genetic Counseling
Session Chairs: Oncology, Genetics - 🕥 10:30 – 11:00 | The New Challenge for Genetic Counselors: MINAS and Multigenic Inheritance
- 🕚 11:00 – 11:30 | The Burden of Genetic Knowledge: Ethical Boundaries in Counseling
- 🛰 11:30 – 12:00 | Satellite Symposium
Moderator to be approved in coordination with sponsor - 🍽 12:00 – 13:30 | Lunch Break
- 🛰 13:30 – 14:00 | Satellite Symposium
Moderator to be approved in coordination with sponsor - 🧬 Designing Tomorrow: Clinical Applications of Preimplantation Genetic Testing
Session Chairs: Medical Genetics, Reproductive Medicine - 🕑 14:00 – 14:30 | Preimplantation Genetic Testing: Principles and Emerging Technologies
- 🕝 14:30 – 15:00 | From Lab to Life: Clinical Applications of Preimplantation Genetic Testing
- ☕ 15:00 – 15:30 | Coffee Break
- 👶 Inherited Risk, Early Onset: Hereditary Cancer Syndromes in Childhood
Session Chairs: Pediatric Oncologist, Genetics - 🕞 15:30 – 16:00 | Genetic Predisposition in Pediatric Cancers: When Should We Suspect It?
- 🕓 16:00 – 16:30 | Fanconi Anemia and Other Inherited Bone Marrow Failure Syndromes: A Path to Malignancy
- 🕟 16:30 – 17:00 | Clues of Hereditary Predisposition in Pediatric Sarcomas, Leukemia, and Brain Tumors
- 🧒 17:00 – 17:30 | Pediatric Herediboard
📅 February 8, 2026 – Sunday: Closing Day – General Evaluation and Awards Ceremony
The final day of the congress celebrates interactive knowledge sharing and honors outstanding contributions. The program concludes with the highly anticipated Heredity Slam and the official Award Ceremony.
- 🎤 09:00 – 10:30 | Heredity Slam
Selected presenters will share 5–6 rapid-fire case or abstract presentations
Format: 2 moderators and 4 on-stage expert jury members - ☕ 10:30 – 11:00 | Coffee Break
- 🏆 11:00 – 12:00 | Award Ceremony and Closing Remarks
